vTv Therapeutics Files 8-K
Ticker: VTVT · Form: 8-K · Filed: Mar 5, 2024 · CIK: 1641489
| Field | Detail |
|---|---|
| Company | Vtv Therapeutics Inc. (VTVT) |
| Form Type | 8-K |
| Filed Date | Mar 5, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, regulatory-filing, SEC
Related Tickers: VTVT
TL;DR
vTv Therapeutics filed a routine 8-K, no major news.
AI Summary
On March 5, 2024, vTv Therapeutics Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. No specific financial figures or material events were detailed in the provided excerpt, but it confirms the company's reporting status.
Why It Matters
This filing indicates vTv Therapeutics is meeting its regulatory reporting obligations with the SEC, which is standard for publicly traded companies.
Risk Assessment
Risk Level: low — This is a standard regulatory filing with no new material information or significant financial changes disclosed in the provided text.
Key Players & Entities
- vTv Therapeutics Inc. (company) — Registrant
- 0001641489-24-000005 (dollar_amount) — Accession Number
- March 5, 2024 (date) — Date of Report
FAQ
What is the purpose of this 8-K filing for vTv Therapeutics Inc.?
The filing is primarily for Regulation FD Disclosure and to report Financial Statements and Exhibits, as indicated by the Item Information section.
What is the date of the earliest event reported in this filing?
The date of the earliest event reported is March 5, 2024.
What is the principal executive office address for vTv Therapeutics Inc.?
The address is 3980 Premier Drive, Suite 310, High Point, NC 27265.
What is the company's IRS Employer Identification Number?
The IRS Employer Identification Number is 47-3916571.
Under which stock exchange is vTv Therapeutics Inc. listed?
vTv Therapeutics Inc. is listed on Nasdaq.
Filing Stats: 547 words · 2 min read · ~2 pages · Grade level 10.8 · Accepted 2024-03-05 08:04:31
Key Financial Figures
- $0.01 — stered Class A common stock, par value $0.01 per share VTVT Nasdaq Capital Market
Filing Documents
- vtvt-20240305.htm (8-K) — 25KB
- vtvtherapeuticsdeck_non-.htm (EX-99.1) — 17KB
- vtvtherapeuticsdeck_non-001.jpg (GRAPHIC) — 59KB
- vtvtherapeuticsdeck_non-002.jpg (GRAPHIC) — 254KB
- vtvtherapeuticsdeck_non-003.jpg (GRAPHIC) — 93KB
- vtvtherapeuticsdeck_non-004.jpg (GRAPHIC) — 106KB
- vtvtherapeuticsdeck_non-005.jpg (GRAPHIC) — 94KB
- vtvtherapeuticsdeck_non-006.jpg (GRAPHIC) — 127KB
- vtvtherapeuticsdeck_non-007.jpg (GRAPHIC) — 153KB
- vtvtherapeuticsdeck_non-008.jpg (GRAPHIC) — 106KB
- vtvtherapeuticsdeck_non-009.jpg (GRAPHIC) — 96KB
- vtvtherapeuticsdeck_non-010.jpg (GRAPHIC) — 90KB
- vtvtherapeuticsdeck_non-011.jpg (GRAPHIC) — 92KB
- vtvtherapeuticsdeck_non-012.jpg (GRAPHIC) — 93KB
- vtvtherapeuticsdeck_non-013.jpg (GRAPHIC) — 122KB
- vtvtherapeuticsdeck_non-014.jpg (GRAPHIC) — 116KB
- vtvtherapeuticsdeck_non-015.jpg (GRAPHIC) — 122KB
- vtvtherapeuticsdeck_non-016.jpg (GRAPHIC) — 96KB
- 0001641489-24-000005.txt ( ) — 2678KB
- vtvt-20240305.xsd (EX-101.SCH) — 2KB
- vtvt-20240305_lab.xml (EX-101.LAB) — 23KB
- vtvt-20240305_pre.xml (EX-101.PRE) — 12KB
- vtvt-20240305_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure On March 5, 2024, vTv Therapeutics, Inc., (the "Company") posted on its website an updated slide presentation, which is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein. Representatives of the Company will use the presentation in various meetings with investors, analysts and other parties from time to time. This presentation may be amended or updated at any time and from time to time through another Current Report on Form 8-K, a later Company filing or other means. The information in this Item 7.01 (including Exhibit 99.1) shall not be deemed to be "filed" for purposes of, or otherwise subject to the liabilities of, Section 18 of the Exchange Act, nor shall it be deemed to be incorporated by reference in any filing under the 33 Act or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 99.1 vTv Therapeutics' Investor Presentation dated March 2024 104 Cover Page Interactive Data File (embedded within Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. VTV THERAPEUTICS INC. By: /s/ Paul J. Sekhri Name: Paul J. Sekhri Title: President and Chief Executive Officer Dated: March 5, 2024